← Back to Search

Monoclonal Antibodies

Ivonescimab for Squamous Cell Carcinoma

Phase 2
Waitlist Available
Led By Aung Naing, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Ability to understand and willingness to sign informed consent form prior to initiation of the study and any study procedures.
* Age ≥18 years.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year.
Awards & highlights

Summary

To learn if ivonescimab can help to control advanced cSCC. The safety and effects of ivonescimab will also be studied.

Eligible Conditions
  • Squamous Cell Carcinoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety and adverse events (AEs)

Trial Design

1Treatment groups
Experimental Treatment
Group I: IvonescimabExperimental Treatment1 Intervention
Participants found to be eligible to take part in this study, you will receive ivonescimab by vein over about 1-2 hours on Day 1 of each 21-day cycle (1 time every 3 weeks).

Find a Location

Who is running the clinical trial?

Summit TherapeuticsIndustry Sponsor
12 Previous Clinical Trials
2,721 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
3,030 Previous Clinical Trials
1,797,223 Total Patients Enrolled
Aung Naing, MDPrincipal InvestigatorM.D. Anderson Cancer Center
14 Previous Clinical Trials
1,753 Total Patients Enrolled
~16 spots leftby Sep 2028